All In Biotech

Drug Trial Radar · NCT07058025

Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants

Mesenchymal Stromal Cells in Extreme Preterm Infants at Risk of Developing Bronchopulmonary Dysplasia - A Phase 2 Multi-Centre Double Blind Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Jul 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

168

Planned (sponsor's estimate)

Start

Oct 1, 2025

Primary completion

Sep 30, 2028

Study completion Sep 30, 2038

Sponsor

Lead sponsor
Ottawa Hospital Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Canadian Institutes of Health Research (CIHR); Stem Cell Network
First posted
Jul 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 4 days, up to 14 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial aims to evaluate the safety and efficacy of mesenchymal stromal cell (MSC) therapy in extreme preterm infants to prevent bronchopulmonary dysplasia, the main respiratory complication of preterm birth. Study participants will receive either multiple intravenous doses (total of 3 doses) of MSC derived from human donor umbilical cord tissue (intervention group) or no uc-MSC injection (control group) to confirm the safety of IV MSC in extreme preterm infants and evaluate the potential benefit of MSC therapy on their respiratory health as well as on other complications related to preterm birth.

Conditions

  • Bronchopulmonary Dysplasia (BPD)
  • ELGAN (22-28SA)

Interventions

  • Human Allogenic Umbilical Cord Mesenchymal Stromal CellsBiological

    IV administration of uc-MSC every 7 days ± 1 day for 3 weeks. Randomized double blinded

  • Sham procedure controlOther

    Sham procedure (mimic IV catheter insertion adn cell product infusion behing a screen). Repeated weekly for 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of mechanical ventilation-free days accounting for mortalityTime frame: 120 days

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Royal Alexandra Hospital/Stollery Children's Hospital

    Edmonton, Alberta, Canada

  • McMaster Children's Hospital

    Hamilton, Ontario, Canada

  • The Ottawa Hospital

    Ottawa, Ontario, Canada

  • Sunnybrook Health Sciences Ctr

    Toronto, Ontario, Canada

  • Mount Sinai Hospital

    Toronto, Ontario, Canada

  • CHU Sainte-Justine

    Montreal, Quebec, Canada

  • McGill Montreal Children's Hospital

    Montreal, Quebec, Canada

  • Université Laval

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.